Product Information
PIMOZIDE 2 MG TABLET is a generic product labeled by Endo USA Inc., priced at $1.6400 per EA under NDC 49884034801. Its NADAC has been published 346 times since May 18, 2016.
FDA first approved this application on Sep 28, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Endo USA Inc.NDC
49884034801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PIMOZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204521FDA Approved
9/28/2015
TE Code
AB
On Market Since
9/28/2015
Pharmacological Classes
Price Statistics
The NADAC for PIMOZIDE 2 MG TABLET has been published 346 times since May 18, 2016, and over the history we have for it it has declined 11.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.6400 per EA |
|---|---|
| All-time high | $2.0100 (Sep 14, 2016) |
| All-time low | $1.4222 (May 22, 2024) |
| 52-week high | $1.7135 |
| 52-week low | $1.6400 |
| Median price | $1.7334 |
| Average price | $1.7522 |
| Largest weekly change | -17.4% (May 22, 2024) |
| Weeks tracked | 346 |
| Tracking since | May 18, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Pimozide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pimozide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Typical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIMOZIDE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PIMOZIDE 2 MG TABLET, manufactured by Endo USA Inc., is $1.6400 per EA (NDC 49884034801), effective Sep 30, 2026.
How has the price of PIMOZIDE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for PIMOZIDE 2 MG TABLET has declined 11.2%. It has been tracked across 346 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for PIMOZIDE 2 MG TABLET?
Since May 18, 2016, the NADAC for PIMOZIDE 2 MG TABLET has ranged from a low of $1.4222 (May 22, 2024) to a high of $2.0100 (Sep 14, 2016), with a median of $1.7334 per EA.
Are there cheaper alternatives to PIMOZIDE 2 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PIMOZIDE 2 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PIMOZIDE 2 MG TABLET?
PIMOZIDE 2 MG TABLET (NDC 49884034801) is labeled by Endo USA Inc., and CMS classifies it as a generic product.